Model AZD5055 - Phase I - Idiopathic Pulmonary Fibrosis

Mechanism: Porcupine inhibitor. Area under investigation: idiopathic pulmonary fibrosis. Date commenced phase: Q4 2021. Estimated Filing Acceptance: Country US: EU: Japan: China. Additional information: Molecule size: Small molecule. Status change: